<DOC>
	<DOCNO>NCT02771314</DOCNO>
	<brief_summary>Based possibility plasma circulate tumor cell ( CTCs ) ( `` liquid biopsy '' ) may offer , consider could feasible longitudinally monitor genetic evolution biologic characteristic CTCs , use Circulating tumor DNA ( ctDNA ) CTCs source biologic material . This approach could provide information regard genetic/molecular change associate primary acquire resistance AZD9291 , thus , facilitate appropriately adapt tailor treatment particular group NSCLC patient . It recently report detection resistant clone , base tumor-associated genetic aberration blood , identify treatment resistance 10 month earlier radiological method provide , thus , potential early switch non cross-resistant therapy order improve patient ' outcome .</brief_summary>
	<brief_title>Liquid Biopsy Tool Evaluate Resistance First Third ( AZD9291 ) ( EGFR ) ( TKIs ) ( EGFR ) Mutant NSCLC</brief_title>
	<detailed_description>Lung cancer among common tumor type represent 13 % newly diagnose cancer worldwide . Both absolute relative frequency lung cancer rise dramatically . Unfortunately , lung cancer remain far leading cause cancer-related death , account 18 % total number death . Non Small Lung Cancer ( NSCLC ) account 85 % case lung cancer classify several subtypes base various molecular histological feature . The initial dose 80 mg AZD9291 administer daily orally fast state reduce 40 mg AZD9291 daily circumstance Single arm , open-label , phase II , multicenter study . NSCLC patient activate EGFR mutation , front line treatment first generation EGFR TKIs accord physician ' choice present disease progression , treat single agent AZD9291 . The patient follow every 3 month detection mutation ( T790M ) , ( C797S ) , ( L858R ) , del 19 EGFR mutation well mutation [ ( KRAS ) / ( NRAS ) , ( BRAF ) , ( PI3K ) ] serum/plasma , determination serum level Hepatocyte Growth Factor ( HGF ) , presence T790M ( + ) C797S ( + ) CTCs well molecular ( c-MET ) ( HER2 amplification ) phenotypic characterization CTCs use filtration platform ( ISET ) . The elimination emergence circulate tumor biomarkers correlate patient ' clinical outcome [ objective response treatment ( ORR ) , ( PFS ) ( OS ) ] . There specific control group study . Biomarkers profile baseline use internal control patient monitor change throughout treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Both sexes 3 . Histologically cytologically document NSCLC 4 . Stage 3b ( IIIb ) amenable radical therapy stage IV 5 . Presence EGFR activate mutation ( exon 19 deletion L858R exon 21 ) 6 . First second line treatment EGFR TKIs 7 . Performance status ( ECOG ) : 01 8 . Measurable evaluable disease 9 . Adequate organ function test ( Hb &gt; =10g/dL , white blood cell ( WBC ) &gt; =3.0 x 10^9/L , neutrophil count &gt; =1.5 x 10^9/L , plateletsâ‰¥100 x 10^9/L , Creatinine clearance &gt; =50 mL/min , Total bilirubin= &lt; 1.5 X UNL , aspartate aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) Alkaline phosphatase ( ALP ) = &lt; 2.5 x UNL ) 10 . Normal QT interval ECG 11 . Central nervous system ( CNS ) metastases allow provided irradiated patient clinically stable 12 . Women child bear potential men require use adequate contraceptive measure 13 . Life expectancy least 3 month 14 . Written inform consent 1 . History serious drug allergy 2 . Refractory nausea , vomit chronic gastrointestinal disease 3 . Any following cardiac criterion : Mean rest correct QT interval ( QTc ) &gt; 470 msec , obtain 3 ECGs , use screen clinic ECG machinederived QTc value . Any clinically important abnormality rhythm , conduction , morphology rest ECG . Any factor increase risk QTc prolongation risk arrhythmic event unexplained sudden death 40 year age firstdegree relative concomitant medication know prolong QT interval . 4 . Severe uncontrolled systemic liver disease , include know hepatitis B , hepatitis C , Human Immunodeficiency virus ( HIV ) infection 5 . Interstitial lung disease pulmonary fibrosis 6 . Pregnancy , lactation concomitant serious medical condition 7 . Other concurrent active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>AZD9291</keyword>
	<keyword>&gt; = 2nd line</keyword>
	<keyword>liquid biopsy</keyword>
	<keyword>EGFR TKIs</keyword>
	<keyword>EGFR mutant</keyword>
</DOC>